California AG Sues Big Pharma Drugmakers Over Insulin Price Gouging

by | Jan 14, 2023 | Human Rights & Justice

Photo by Mykenzie Johnson

California AG Sues Big Pharma Drugmakers Over Insulin Price Gouging

by | Jan 14, 2023 | Human Rights & Justice

Photo by Mykenzie Johnson
California follows other states in going after insulin companies and pharmaceutical middlemen, but California is taking an aggressive approach by charging the companies with violating the state’s Unfair Competition Law.

California Attorney General Rob Bonta on Thursday sued the six major companies that dominate the U.S. insulin market, ratcheting up the state’s assault on a profitable industry for artificially jacking up prices and making the indispensable drug less accessible for diabetes patients.

The 47-page civil complaint alleges three pharmaceutical companies that control the insulin market — Eli Lilly and Co., Sanofi, and Novo Nordisk — are violating California law by unfairly and illegally driving up the cost of the drug. It also targets three distribution middlemen known as pharmacy benefit managers: CVS Caremark, Express Scripts, and OptumRx.

“We’re going to level the playing field and make this life-saving drug more affordable for all who need it, by putting an end to Big Pharma’s big profit scheme,” Bonta said at a news conference after filing the lawsuit in a state court in Los Angeles. “These six companies are complicit in aggressively hiking the list price of insulin, at the expense of patients.”

In the lawsuit, Bonta argued that prices have skyrocketed and that some patients have been forced to ration their medicine or forgo buying insulin altogether. The attorney general said a vial of insulin, which diabetics rely on to control blood sugar, cost $25 a couple of decades ago but now costs about $300.

A 2021 U.S. Senate investigation found that the price of a long-acting insulin pen made by Novo Nordisk jumped 52% from 2014 to 2019 and that the price of a rapid-acting pen from Sanofi shot up about 70%. From 2013 to 2017, Eli Lilly had a 64% increase on a rapid-acting pen. The investigation implicated drug manufacturers and pharmacy benefit managers in the increases, saying they perpetuated artificially high insulin prices.

“California diabetics who require insulin to survive and who are exposed to insulin’s full price, such as uninsured consumers and consumers with high deductible insurance plans, pay thousands of dollars per year for insulin,” according to the complaint.

Eli Lilly spokesperson Daphne Dorsey said the company is “disappointed by the California attorney general’s false allegations,” arguing that the average monthly out-of-pocket cost of insulin has fallen 44% over the past five years, and the drug is available to anyone “for $35 or less.”

Mike DeAngelis, a spokesperson for CVS, said it would vigorously defend itself, saying that pharmaceutical companies alone set list prices. “Nothing in our agreements prevents drug manufacturers from lowering the prices of their insulin products, and we would welcome such action. Allegations that we play any role in determining the prices charged by manufacturers are false,” he said.

OptumRx, a division of UnitedHealthcare, said it welcomes the opportunity to show California “how we work every day to provide people with access to affordable drugs, including insulin.” And company spokesperson Isaac Sorensen said it has eliminated out-of-pocket costs for insulin.

Other companies targeted in the suit, and the trade associations that represent them, did not immediately respond to inquiries seeking comment, or declined to comment on the lawsuit. Instead, they either blamed one another for price increases or outlined their efforts to lower costs. Costs for consumers vary widely depending on insurance coverage and severity of illness.

California follows other states, including Arkansas, Kansas, and Illinois, in going after insulin companies and pharmaceutical middlemen, but Bonta said California is taking an aggressive approach by charging the companies with violating the state’s Unfair Competition Law, which could carry significant civil penalties and potentially lead to millions of dollars in restitution for Californians.

If the state prevails in court, the cost of insulin could be “massively decreased” because the companies would no longer be allowed to spike prices, Bonta said.

Bonta joins fellow Democratic leaders in targeting the pharmaceutical industry. Gov. Gavin Newsom has launched an ambitious plan to put the nation’s most populous state in the business of making its own brand of insulin as a way to bring down prices for roughly 3.2 million diabetic Californians who rely on the drug.

“Big Pharma continues to put profits over people — driving up drug prices and restricting access to this vital medicine,” Newsom spokesperson Brandon Richards told KHN. “That is why California is moving towards manufacturing our own affordable insulin.”

By launching an aggressive attack against the pharmaceutical industry, California is also wading into a popular political fight. Many Americans express outrage at drug costs while manufacturers blame pharmacy middlemen and health insurers. Meanwhile, the middlemen point the finger back at drugmakers.

Edwin Park, a California-based research professor with Georgetown University’s Center for Children and Families, said California’s push to enter the generic drug business, while also suing the pharmaceutical industry, could ultimately lead to lower patient costs at the pharmacy counter.

“It can put downward pressure on list prices,” Park said, referring to the sticker price of drugs. “And that can lead to lower out-of-pocket costs.”

There isn’t much transparency in how drug prices are set in the U.S. Manufacturers are predominantly to blame for high drug costs, because they set the list prices, Park said. A growing body of research also indicates that the pharmaceutical middlemen are a prime driver of high patient drug costs. To lower prices, it’s critical to target the entire supply chain, experts say.

“The list price has definitely gone up,” said Dr. Neeraj Sood, a professor of health policy, medicine, and business at the University of Southern California who has studied drivers of high insulin costs. “But over time a larger share of the money is going to the middlemen rather than the manufacturers.”

This story was produced by KHN, which publishes California Healthline, an editorially independent service of the California Health Care Foundation.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

Republished with permission from Kaiser Health News, by

Kaiser Health News

Kaiser Health News

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Follow Us

Related Articles

Feb 03 2023

The 5th U.S. Circuit Court Deems Gun Possession More Important Than Family Safety

There is no real doubt that the 5th Circuit’s decision is going to lead to more abusers murdering their wives and girlfriends.
Attendees hold signs as they listen to speakers during a rally calling for an end to corporate money in politics and to mark the fifth anniversary of the Supreme Court's Citizens United decision on January 21, 2015 in Washington, D.C. (Photo: Drew Angerer/Getty Images)
Jan 20 2023

House Democrats Introduce Constitutional Amendment to Overturn Citizens United

The Citizens United decision allowed special interest groups and corporations to create super PACs, to accept unlimited donations—including from “dark money...
Dec 26 2022

The Christmas Cruelty of Greg Abbott

Three buses coming from Texas dropped off about 140 recent migrants—including babies and young children—near VP Harris’ residence in Washington, D.C., in historically...
Dec 24 2022

How the January 6th Committee Tackled an Unprecedented Attack With a Time-Tested Inquiry

Despite the unprecedented action by the January 6th committee of the criminal referral of the ex-president for a variety of charges, Congressional committees have a...
Dec 20 2022

A Constitutional Law Expert Explains What the Criminal Referral of Trump Means

A professor of constitutional law helps explain why the recommended charges against Trump are important, where they fall short—and what could come next.
Dec 19 2022

Students With Disabilities—The Illinois School That Routinely Has Students Arrested

An Illinois school for students with disabilities has routinely used the police to handle discipline, resulting in the highest arrest rate of any district in the...
Dec 18 2022

The Danger of the Republican’s Bogus ‘Independent State Legislatures’ Theory

Republicans support the ‘Independent State Legislatures’ theory because they’ve given up on democracy. They seek to make it harder for people to vote and box them into...
Dec 15 2022

What America Can Learn About Medical Debt From Germany’s Coal Miners

Germany’s limits on how much patients pay out-of-pocket at the doctor’s office have been critical to ensuring people get needed care, especially in a mining region...
Dec 10 2022

The Details Behind Brittney Griner’s Long Road Home

Outside of the public eye, pleas, letters and negotiations were in action for months to gain the release of Brittney Griner from her imprisonment in Russia.
four people inside mart
Dec 06 2022

Drug Prices Will Finally Start to Decrease for Medicare Recipients

While pharmaceutical companies argued against Medicare price negotiation, saying it would harm research and development of new drugs and innovation, polling has found...
Subscribe for Updates!

Subscribe for Updates!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Pin It on Pinterest

Share This